Sodium tanshinone IIA sulfonate on LV remodeling in STEMI patients following PCI
Left Ventricular Remodeling · Acute Myocardial Infarction
Enrolment: 60 · Results not recorded
Loading the evidence…
Nutraceutical
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Left Ventricular Remodeling · Acute Myocardial Infarction
Enrolment: 60 · Results not recorded
Pulmonary Hypertension · Pulmonary Arterial Hypertension
Enrolment: 90 · Results not recorded
COVID-19
Enrolment: 80 · Results not recorded
Polycystic Ovary Syndrome
Enrolment: 100 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Seawater aspiration-induced lung injury (intratracheal seawater)
Tanshinone IIA attenuated seawater aspiration-induced lung injury in rats partly by downregulating MIF and NF-kB and reducing IL-6 and TNF-alpha.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
Model: Seawater aspiration-induced acute lung injury (intratracheal seawater installation)
Tanshinone IIA reduced AQP1 and AQP5 over-expression and alleviated seawater aspiration-induced lung oedema, injury and gas-exchange impairment.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.